
    
      Primary Objectives

        -  to determine the maximum tolerated dose (MTD) of nal-IRI (ONIVYDE速) in combination with
           TAS-102 (LONSURF速)

        -  to evaluate the toxicity profile of the combination therapy Secondary Objectives

        -  to evaluate the preliminary efficacy of the combination therapy of nal-IRI (ONIVYDE速)
           and TAS-102 (LONSURF速)

        -  to study the pharmacokinetics of the combination therapy

      A phase 1 study with a classical 3 + 3 dose escalation design. The target population is
      patients who have pathologically confirmed malignant solid tumors with no standard treatment
      available.
    
  